<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00255983</url>
  </required_header>
  <id_info>
    <org_study_id>REP-FAR-005</org_study_id>
    <nct_id>NCT00255983</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis</brief_title>
  <official_title>Prospective, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil 600 mg PO, BID for 5 Days Versus Placebo In the Treatment of Acute Exacerbation of Chronic Bronchitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Replidyne</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>INC Research Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Replidyne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identifying the role of antibiotics in the treatment of subjects with a microbiologically
      documented acute exacerbation of chronic bronchitis (AECB) is the purpose of this clinical
      trial. The trial has been designed to evaluate the efficacy and safety of faropenem medoxomil
      versus placebo in the treatment of subjects with microbiologically documented AECB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, multi-national, prospective, randomized, double-blind,
      placebo-controlled study to evaluate the efficacy and safety/tolerability of faropenem
      medoxomil versus placebo in the treatment of subjects with a primary diagnosis of AECB. All
      subjects will have a pre-therapy sputum specimen obtained for culture and susceptibility
      testing.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    financial reasons
  </why_stopped>
  <start_date>December 2005</start_date>
  <completion_date type="Anticipated">June 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>â€¢ Clinical response at test of cure.</measure>
    <time_frame>Day 8 to 12</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">491</enrollment>
  <condition>Chronic Bronchitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>faropenem medoxomil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faropenem medoxomil</intervention_name>
    <description>600 mg BID for 5 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo tablets BID for 5 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant female outpatients age greater than or equal 35 years with
             significant COPD (GOLD criteria I, IIA or IIB), chronic cough and sputum production
             and an acute exacerbation

        Exclusion Criteria:

          -  Gold criteria III
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger M Echols, MD</last_name>
    <role>Study Director</role>
    <affiliation>Replidyne, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Multicenter</name>
      <address>
        <city>New Hope</city>
        <state>Pennsylvania</state>
        <zip>18938</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2005</study_first_submitted>
  <study_first_submitted_qc>November 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>May 30, 2008</last_update_submitted>
  <last_update_submitted_qc>May 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Robert Tosiello</name_title>
    <organization>Replidyne</organization>
  </responsible_party>
  <keyword>bronchitis</keyword>
  <keyword>AECB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>beta-Lactams</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

